HealthQuill depression treatment
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Pharma

Johnson & Johnson ends late-stage trial of depression drug aticaprant

HQ Team March 7, 2025: Johnson & Johnson is discontinuing the Phase 3 VENTURA clinical trial of its experimental depression drug aticaprant after.

Read More